Skip to main content

Ekso Bionics

Category: Robotics / Embodied AI

A leading developer of wearable robotic exoskeleton suits designed to enhance human mobility and physical capability in medical and industrial settings. Ekso Bionics was founded in 2005. The company is led by Scott Davis. Based in San Rafael, USA. Team size: 100-200. Total funding raised: $185.0M. Latest round: Strategic Merger Agreement. Key investors include CMEA Capital, Applied Digital, Intel Capital, Liberty Mutual Strategic Ventures.

Founded
2005
Headquarters
San Rafael, USA
Team size
100-200
Total funding
$185.0M

Value proposition

Enhances patient recovery outcomes through AI-driven gait training while reducing physical strain and injury risk for industrial workers through ergonomic augmentation.

Products and solutions

EksoNR: The first FDA-cleared exoskeleton for stroke and spinal cord injury rehabilitation., Indego Therapy & Indego Personal: Lightweight lower-limb exoskeletons for clinical and home use (acquired from Parker Hannifin)., Ekso EVO: An upper-body lifting vest designed to reduce fatigue and injury in industrial overhead work., EksoUE: A wearable upper-extremity medical device for patients with upper-limb paralysis or fatigue., EksoView: A proprietary cloud-based software platform that provides real-time analytics and patient progress tracking.

Unique value

The first company to receive FDA clearance for exoskeleton use with stroke, acquired the Indego product line to dominate the personal mobility market, and is now pivoting toward AI-integrated high-performance computing (HPC) for robotics.

Target customer

Inpatient and outpatient rehabilitation centers, hospitals, manufacturing and construction corporations, and individuals with lower-extremity paralysis.

Industries served

Healthcare & Neurorehabilitation, Manufacturing & Logistics, Construction, Defense & Aerospace (Historical/R&D)

Technology advantage

Proprietary 'Smart Assist' software allows for adaptive gait adjustment in real-time based on patient effort; the strategic merger with Applied Digital provides a unique vertical integration of AI compute power with physical robotic hardware.

How they differentiate

Ekso Bionics differentiates through its 'Smart Assist' software, which allows for real-time adaptive gait adjustment based on patient effort, and its status as the first company to receive FDA clearance for stroke and acquired brain injury (ABI) rehabilitation. Unlike competitors focused solely on medical or industrial, Ekso maintains a strong dual-presence in both clinical neurorehabilitation and industrial ergonomics.

Main competitors

Lifeward (formerly ReWalk Robotics), Cyberdyne Inc., Ottobock (SuitX)

Key partnerships

Applied Digital (Strategic merger partner for AI/HPC integration), Parker Hannifin (Acquisition of HMC business unit), Shepherd Center & Kessler Foundation (Clinical research and validation partners), Ford Motor Company (Early industrial pilot partner)

Notable customers

Kessler Foundation, Shepherd Center, Ford Motor Company, BMW, U.S. Department of Defense

Major milestones

Received first-ever FDA clearance for exoskeleton use in stroke rehabilitation (2016)., Acquired the Human Motion and Control (HMC) business unit from Parker Hannifin, including the Indego product line (2023)., Announced strategic merger with Applied Digital to form 'ChronoScale' to integrate AI and HPC into robotics (2024).

Growth metrics

Reported $18.3M in revenue for FY 2023, representing a 42% increase over 2022; gross margin improved to 49% following the Indego acquisition.

Market positioning

Premium medical robotics leader and industrial ergonomic pioneer transitioning into an AI-integrated high-performance computing (HPC) robotics firm.

Geographic focus

Global, with primary revenue hubs in North America and Europe (EMEA), and expanding clinical partnerships in the Asia-Pacific region.

Patents and IP

Holds an extensive intellectual property portfolio with over 300 granted or pending patents globally covering exoskeleton structures, control systems, and sensor technologies.

About Scott Davis

Scott Davis has over 20 years of leadership experience in the healthcare and medical technology industries. He was appointed CEO of Ekso Bionics in December 2022, having previously served as the company's President and COO (2022) and Executive Vice President of Strategy and Corporate Development (2021). His career includes a 15-year tenure at GE Healthcare, where he held several senior leadership roles, including Vice President and General Manager of global business units focused on diagnostic imaging and digital health solutions.

Official website: